Purpose: Metastatic castration-resistant prostate cancer (mCRPC) resistant to androgen receptor signaling inhibitors (ARSI) is often lethal. Liquid biopsy biomarkers for this deadly form of disease remain under investigation, and underpinning mechanisms remain ill-understood. Experimental Design: We applied targeted cell-free DNA (cfDNA) sequencing to 126 patients with mCRPC from three academic cancer centers and separately performed genome-wide cfDNA methylation sequencing on 43 plasma samples collected prior to the initiation of first-line ARSI treatment. To analyze the genome-wide sequencing data, we performed nucleosome positioning and differential methylated region analysis. We additionally analyzed single-cell and bulk RNA sequencing data from 14 and 80 patients with mCRPC, respectively, to develop and validate a stem-like signature, which we inferred from cfDNA. Results: Targeted cfDNA sequencing detected AR/enhancer alterations prior to first-line ARSIs that correlated with significantly worse progression-free survival (P = 0.01; HR = 2.12) and overall survival (P = 0.02; HR = 2.48). Plasma methylome analysis revealed that AR/enhancer lethal mCRPC patients have significantly higher promoter-level hypomethylation than AR/enhancer wild-type mCRPC patients (P < 0.0001). Moreover, gene ontology and CytoTRACE analysis of nucleosomally more accessible transcription factors in cfDNA revealed enrichment for stemness-associated transcription factors in patients with lethal mCRPC. The resulting stemness signature was then validated in a completely held-out cohort of 80 patients with mCRPC profiled by tumor RNA sequencing. Conclusions: We analyzed a total of 220 patients with mCRPC, validated the importance of cell-free AR/enhancer alterations as a prognostic biomarker in lethal mCRPC, and showed that the underlying mechanism for lethality involves reprogramming developmental states toward increased stemness. See related commentary by Nawfal et al., p. 7
Summary: Metastatic castration-resistant prostate cancer (mCRPC) resistant to androgen receptor (AR)-targeted agents is often lethal. Unfortunately, biomarkers for this deadly disease remain under investigation, and underpinning mechanisms are ill-understood. Here, we applied deep sequencing to ∼100 mCRPC patients prior to the initiation of first-line AR-targeted therapy, which detected AR /enhancer alterations in over a third of patients, which correlated with lethality. To delve into the mechanism underlying why these patients with cell-free AR /enhancer alterations developed more lethal prostate cancer, we next performed genome-wide cell-free DNA epigenomics. Strikingly, we found that binding sites for transcription factors associated with developmental stemness were nucleosomally more accessible. These results were corroborated using cell-free DNA methylation data, as well as tumor RNA sequencing from a held-out cohort of mCRPC patients. Thus, we validated the importance of AR /enhancer alterations as a prognostic biomarker in lethal mCRPC, and showed that the underlying mechanism for lethality involves reprogramming developmental states toward increased stemness.
Table S1. Patient characteristics. Table S2. Patients-level clinical treatment and outcome details. Table S3. Mutations detected in patient cell-free DNA by EnhanceAR-Seq. Table S4. Copy number alterations detected in patient cell-free DNA by EnhanceAR-Seq. Table S5. Structural variations detected in patient cell-free DNA by EnhanceAR-Seq. Table S6. Cox regression for progression-free survival with baseline covariates including altered AR enhancer detected in pre-treatment plasma. Table S7. Cox regression for overall survival with baseline covariates including altered AR enhancer in pre-treatment samples. Table S8. Clinical characteristics of the metastatic prostate cancer cohort. Table S9. Patient plasma cell-free DNA methylation sequencing metrics. Table S10. Hypomethylated DMRs in AR/enhancer altered lethal mCRPC patients. Table S11. Hypermethylated DMRs in AR/enhancer altered lethal mCRPC patients. Table S12. Central coverage of transcription factor binding sites (TFBSs) for most accessible transcription factors in AR/enhancer altered lethal mCRPC. Table S13. Central coverage of transcription factor binding sites (TFBSs) for least accessible transcription factors in AR/enhancer altered lethal mCRPC. Table S14. Multivariate Cox regression for progression-free survival.
Supplementary Figure S1. Genomic landscape of metastatic castration-resistant prostate cancer (mCRPC) samples profiled using EnhanceAR-Seq. EnhanceAR-Seq, Enhancer and neighboring loci of Androgen Receptor Sequencing.
Supplementary Figure S7. Distribution of differentially methylated regions in mCRPC plasma cell-free DNA. (A) Distribution of hypomethylated and hypermethylated genic DMRs in pre-treatment plasma cfDNA in AR/enhancer altered lethal mCRPC (compared to AR/enhancer wild-type mCRPC). (B) Genomic annotation of genic DMRs based on their location in the genome. (C) Top 50 hypermethylated DMRs found in pre-treatment plasma cfDNA from AR/enhancer altered lethal mCRPC patients (compared to AR/enhancer wild-type mCRPC). cfDNA, cell-free DNA; CDS, coding sequence; DMRs, differentially methylated regions; mCRPC, metastatic castration-resistant prostate cancer; UTR, untranslated region.
Supplementary Figure S3. Kaplan-Meier analysis of an additional cohort of 27 patients with oligometastatic mCRPC, stratified by AR enhancer amplification status in plasma cell-free DNA. (A) Progression-free survival, (B) radiographic progression-free survival, and (C) overall survival. p values were calculated by the log-rank test.